PIPE-307 is under clinical development by Janssen Pharmaceutica and currently in Phase II for Relapsing Remitting Multiple Sclerosis (RRMS). According to GlobalData, Phase II drugs for Relapsing Remitting Multiple Sclerosis (RRMS) have a 50% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how PIPE-307’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

PIPE-307 overview

PIPE-307 is under development for the treatment of multiple sclerosis and relapsing remitting multiple sclerosis (RRMS). It is administered through oral route as tablets and through intravenous route. It acts by targeting Muscarinic Acetylcholine Receptor M1 (CHRM1).

Janssen Pharmaceutica overview

Janssen Pharmaceutica, a subsidiary of Johnson & Johnson, develops and manufactures new drugs. The company focuses on therapeutic areas such as pulmonary hypertension, oncology, immunology, cardiovascular and metabolic diseases, neurosciences and infectious diseases. Its brands include Akeega, Byannli, Carvykti, Dacogen, Darzalex, Durogesic, Edurant, Eprex, Erleada, Imbruvica, Jcovden, Mvabea, Pariet, Ponvory, Rybrevant, Sibelium, Spravato, Talvey, Tremfya, Uptravi, Velcade, Xeplion and Zytiga, among others. Janssen Pharmaceutica is headquartered in Beerse, Belgium.

For a complete picture of PIPE-307’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 10 June 2024

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.